Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine monotherapy for locally persistent nasopharyngeal carcinoma after radical chemoradiotherapy
ChiCTR1900025216Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Primary endpoint: 3-year progression-free survival. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
capecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR1900025216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025216.